Conservative Management of Pediatric Unicystic Ameloblastoma in a Secondary Healthcare Facility in an Ameloblastoma's High Burden Sub-Saharan Africa: A Report of Two Cases
DOI:
https://doi.org/10.61172/a6xqq144Abstract
Background: Surgical resection is the primary treatment for ameloblastoma but often causes facial disfigurement and complications. Conservative management of unicystic ameloblastoma (UA) may prevent these issues. Clinicians should note that combining marsupialization, enucleation, and Carnoys solution adjuvant therapy restores jawbone health, prevents complications, and improves patients quality of life.
Presentation: Two pediatric casesa 13-year-old boy with a 3-month right mandibular ramus swelling and an 11-year-old boy with a 5-month anterior mandibular swellingpresented at General Hospital Ifako-Ijaiye. Clinical and investigative findings confirmed unicystic mural ameloblastoma.
Intervention: Both underwent marsupialization followed by enucleation with Carnoys solution. Preoperative orthopantomograms showed unilocular radiolucent lesions; postoperative imaging revealed restored bony trabeculae.
Outcome: Successful treatment with no recurrence after one year (ongoing monitoring). There was no clinical or radiographic evidence of recurrence at 1-year follow-up. Planned surveillance per IAOMS guidelines (≥5 years for mural UA)" Conclusion: Conservative UA management with regular follow-up prevents facial disfigurement and complications associated with resection, improving quality of life. These are Nigeria’s first documented pediatric UA cases.
Keywords: unicystic ameloblastoma, marsupialization, enucleation, Carnoys solution.
Downloads
References
REFERENCE:
1. Castano BO, Oluwakuyide RT, Ayodele AOS, Adeshina OA, Adenaike FS, Osobu OM, Obigbesan KO, Faminu EA. Pattern of histologic variants of ameloblastoma in secondary health care facility in Lagos State: A 5 year retrospective study. Nig Dent J; 2023 Jan-Jun; 31(1): 9-26.
2. Ahmed W. Conservative treatment of Unicystic ameloblasoma. Egypt J Oral Maxillofac Surg 2020 June, 11(1): 8-14. DOI: 10.21608/omx.2020.27206.1059
3. Sudhakara KR, Girish SR. Unicystic Ameloblastoma in 6-year-old and its significance. World J Dent, 2011 Oct-Dec; 2(4): 363-366.
4. Lee SM, Ku JK, Leem DH, Bae J, Ko S. Conservative management with Carnoy Solution in ameloblastoma. J Korean Assoc Oral Maxillofac Surg. 2021 Feb; 47(1): 40-46.
5. Demir E, Gunhan O. Conservative treatment of a unicystic ameloblastoma by marsupialization with a favorable response. A case report and review of the literature. Dent Res J 2023; 20:10.
6. Meshram M, Sagarka L, Dhuvad J, Anchlia S, Vyas S, Shah H. Conservative Management of Unicystic ameloblastoma in Young Patients: A Prospective Single-Center Trial and Review of literature. J Maxillo. Oral Surg. 2017 July-Sept; 16(3): 333-341.
7. Sinduja P, Ramani P. Unicystic Ameloblastoma: Treatment outcomes and Risk of Recurrence- A 19-year Institution-Based Study. J Indian Aca Oral Med Radio. 2024 Jul-Sept; 36(3): 248-253.
8. Consolo U, Tongnacci S, Bencivenni D, Felice P, Bellini P. Conservative treatment of unicystic mursal ameloblastoma. Oral Maxillofac Surg Cases. 2020 Sept; 6(3):
9. Anand R, Narwal A, Pandiar D, Kamboj M et al. Clinicopathological Profile of 80 cases of Unicystic Ameloblastoma Aided Modified Philipsen-Reichart Classification and Marx-Stern Classification. Head Neck PAthol. 2021 Sept; 15(3): 875-881.doi: 10.1007/s12105-021-01307-7
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Babalola Oluwole Castano, Remi T Oluwakuyide, Akanbi Clement Oluwarotimi, Augustine Ikponmwosa Edomwonyi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Open Access Statement
- We became fully Open Access since January 2023.
- Our new and archived materials are available free of charge on open basis and under a Creative Commons license as stated below.
Copyright statement
Copyright © 1999 The authors. This work, Nigerian Dental Journal by Nigerian Dental Association is licensed under Creative Commons Attribution 4.0 International License.
